• PDF / 169,214 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 28 Downloads / 156 Views

DOWNLOAD

REPORT

---

1 S

Exacerbation of psoriasis during off-label use: case report A 71-year-old woman experienced exacerbation of psoriasis during off-label treatment with oseltamivir and hydroxychloroquine for COVID-19. The woman was admitted to a pandemic clinic with COVID-19. She had a history of psoriasis, which has been activated occasionally since her childhood. During the admission, she started receiving off-label treatment with oral hydroxychloroquine 2 x 400mg on the first day followed by 2 x 200mg and oral oseltamivir 2 x 75mg. On day 4 of the treatment, she had an exacerbation of psoriasis characterised by silver-scaled psoriatic plaques, which quickly spread all over the body and separated from the surrounding tissue with sharp borders. It was reported that the treatment with oseltamivir and hydroxychloroquine, and her underling COVID-19 had contributed to the exacerbation of psoriasis [outcome not stated]. Kutlu O, et al. A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID-19: Will cases of psoriasis increase after COVID-19 803503988 pandemic?. Dermatologic Therapy 33: No. 4, Jul-Aug 2020. Available from: URL: http://doi.org/10.1111/dth.13383

0114-9954/20/1823-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 26 Sep 2020 No. 1823